Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clazakizumab - CSL Behring/Vitaeris

Next Previous
X
Search
Drug Profile

Clazakizumab - CSL Behring/Vitaeris

Alternative Names: ALD 518; BMS-645429; BMS-945429; CSL-300

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer CSL Behring; ICON; Lundbeck Seattle BioPharmaceuticals Inc.; Vitaeris
  • Class Anti-inflammatories; Antianaemics; Antipsoriatics; Antirheumatics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal transplant rejection
  • Phase II/III Renal failure
  • Phase II COVID 2019 infections; Inflammation
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 08 Apr 2024 CSL Behring terminates a phase III IMAGINE trial in Renal transplant rejection in Austria, Czech Republic, New Zealand, Belgium, South Korea, Taiwan, Australia, Canada, France, Germany, Netherlands, Sweden, Hungary, Spain, USA (SC) due to lack of efficacy/futility at interim analysis (NCT03744910) (EudraCT 2018-003682-34)
  • 18 Jul 2023 Phase-II clinical trials in Inflammation (In the elderly) in USA (SC) (NCT05727384)
  • 29 Nov 2022 Phase-II development in COVID-2019 infections is ongoing in USA (IV) (NCT04343989)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top